Behavioral effects of MK-801 on reserpine-treated mice

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 26, Issue 3, 2002, Pages 487-495

  Dutra, Renata C ^a   Andreazza, Ana Paula ^a   Andreatini, Roberto ^a   Tufik, Sergio ^b   Vital, Maria A B F ^a  

^a UNIVERSIDADE TECNOLÓGICA FEDERAL DO PARANÁ   (Brazil)

^b FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Catalepsy; MK 801; Reserpine; Tongue protrusions; Tremor; Vacuous chewing

Indexed keywords

APOMORPHINE; DIZOCILPINE; DOPAMINE; GLUTAMIC ACID; NEUROTRANSMITTER; RESERPINE;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CATALEPSY; CONTROLLED STUDY; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DRUG INDUCED DISEASE; MASTICATION; MOUSE; NONHUMAN; PARKINSON DISEASE; TARDIVE DYSKINESIA; TREMOR;

ANIMALS; BEHAVIOR, ANIMAL; DISEASE MODELS, ANIMAL; DIZOCILPINE MALEATE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DYSKINESIA, DRUG-INDUCED; MALE; MICE; PARKINSONIAN DISORDERS; RECEPTORS, N-METHYL-D-ASPARTATE; RESERPINE;

EID: 0036200505     PISSN: 02785846     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0278-5846(01)00295-0     Document Type: Article

References (46)

1. The functional anatomy of basal ganglia disorders
2. Levodopa-induced dyskinesias in Parkinson's disease: Is sensitization reversible?
3. Effects of age on a new animal model of tardive diskinesia
4. Monoamine-depleting drugs
5. Pharmacological characteristics of tremor, rigidity and hypokinesia induced by reserpine in rats
6. The group II metabotropic glutamate receptor agonist, DCG-IV, alleviates akinesia following intranigral or intraventricular administration in the reserpine-treated rat
7. Primate models of movement disorders of basal ganglia origin
8. Tremor: Basic mechanisms and clinical aspects
9. Neuroleptic-induced catalepsy as a model of Parkinson's disease: II. Effect of glutamate antagonists
10. On the coexistence of parkinsonism and tardive dyskinesia
11. Tremor
12. Drug-induced parkinsonism and concomitant tardive dyskinesia
13. The neostriatal mosaic: Multiple levels of compartmental organization
14. Animal models of Parkinson's disease: An empirical comparison with the phenomenology of disease in man
15. Glutamate-dopamine interactions in the basal ganglia: Relationship to Parkinson's disease
16. An animal model for coexisting tardive dyskinesia and tardive parkinsonism: A glutamate hypothesis for tardive dyskinesia
17. Uniform frequency of parkinsonian resting tremor in the lips, jaw, tongue and index finger
18. Persistent catalepsy associated with severe dyskinesias in rats treated with chronic injections of haloperidol decanoate
19. Vacuous jaw movements and feeding deficits in rats with ventrolateral striatal dopamine depletion: Possible relation to parkinsonian symptoms
20. Hypokinesia, rigidity and tremor induced by hypothalamic 6-OHDA lesions in the rat
21. Differential effects of intrastriatal and intranigral injections of glutamate antagonists on motor behaviour in the reserpine-treated rat
22. MK-801 reverses haloperidol-induced catalepsy from both striatal and extrastriatal sites in the rat brain
23. NMDA antagonists potentiate antiparkinsonian actions of L-DOPA in monoamine-depleted rats
24. N-Methyl-D-aspartate antagonists stimulate locomotor activity in monoamine-depleted rats: Implications for the therapy of Parkinson's disease
25. Glutamatergic drugs in Parkinson's disease
26. Interactions between a novel cholinergic ion channel agonist, SIB-1765F and L-DOPA in the reserpine model of Parkinson's disease in rats
27. Behavioral and neurochemical effects of chronic administration of reserpine and SKF-38393 in rats
28. Neurochemical changes associated with the persistence of spontaneous oral dyskinesia in rats following chronic reserpine treatment
29. Dose-dependent differences in development of reserpine-induced oral dyskinesia in rats: Support for a model of tardive diskinesia
30. The role of excitatory amino acids in experimental models of Parkinson's disease
31. 2 dopamine receptors in neuroleptic catalepsy
32. Behavioral models of tardive dyskinesia in rodents: A chronological overview
33. Opposite effects of NMDA and AMPA receptor blockade on catalepsy induced by dopamine receptor antagonists
34. Synergy between a selective D1 antagonist and a selective D2 antagonist in the induction of catalepsy
35. Antipsychotic drug mechanisms and neurotransmitter systems in schizophrenia
36. Dopamine receptor abnormalities in the striatum and pallidum in tardive dyskinesia: A postmortem study
37. Vacuous jaw movements induced by acute reserpine and low-dose apomorphine: Possible model of parkinsonian tremor
38. Behavioural pharmacology of glutamate in the basal ganglia
39. Ein eigentumliches syndrom im oralen bereich bei megaphenapplikation. neryenarzt 28, 35. Apud: Casey, D.E. Tardive dyskinesia: Reversible and irreversible?
40. Antiparkinsonian actions of glutamate antagonists, alone and with L-DOPA: A review of evidence and suggestions for possible mechanisms
41. 2 balance in the basal ganglia and its relevance to Parkinson's disease
42. Neuroleptic-induced extrapyramidal reactions: Classification, description and diagnosis
43. Reversible and irreversible dyskinesia after treatment with perphenazine, chlorpromazine, reserpine and eletroconvulsive therapy
44. Effects of monosialoganglioside on a new model of tardive dyskinesia
45. Spontaneous orofacial movements induced in rodents by very long-term neuroleptic-drug administration: Phenomenology, pathophysiology and putative relationship to tardive dyskinesia
46. Spontaneous orofacial dyskinesia and dopaminergic function in rats after 6 months of neuroleptic treatment